Former OpenAI researcher launches $2B AI drug‑discovery startup
Miles Wang, ex‑OpenAI researcher, is founding SynthiAI, an AI‑driven drug discovery platform that has already secured a $2 billion valuation in talks with top VCs. The startup aims to cut lead‑time for new therapeutics by applying large language models to molecular design, signaling a major push of generative AI into pharma.